Tagraxofusp
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tagraxofusp: From CD123+ Hematologic Malignancies to Esotropia
One-Sentence Summary
Tagraxofusp is a CD123-targeted diphtheria toxin fusion protein used in CD123-positive hematologic malignancies (per associated clinical trial documentation, including blastic plasmacytoid dendritic cell neoplasm, BPDCN). The TxGNN model's top-ranked prediction is Esotropia, an ophthalmologic/neuromuscular condition, but this signal is currently supported by 0 clinical trials and 0 publications, and the mechanism of CD123-targeted cytotoxic therapy has no known relationship to strabismus.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed via Norway regulatory data (drug not marketed). Clinical trial documentation in this evidence pack references CD123-positive hematologic malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), AML, and high-risk MDS |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data (DrugBank MOA field) is not available for this candidate (data gap DG002). Based on information embedded in the associated clinical trial records, tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123, used in CD123-positive hematologic malignancies such as BPDCN, AML, and MDS — a mechanism distinct from conventional cytotoxic chemotherapy.
Esotropia is a form of strabismus caused by extraocular muscle or neuromuscular dysfunction, and has no established pathophysiological link to CD123 expression or hematologic malignancy biology. The evidence pack's own repurposing rationale for this candidate explicitly states there is no known mechanistic connection and no supporting clinical or literature evidence. This prediction should be treated as a high-confidence TxGNN embedding-space signal without independent biological or clinical corroboration — a likely model artifact rather than a genuine repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Tagraxofusp is not currently marketed in Norway (market status: 未上市); no marketing authorizations are on record. No Norway product/license information is available for extraction.
Cytotoxicity
Tagraxofusp targets CD123-positive hematologic malignancies (BPDCN/AML/MDS per associated trial documentation) and is classified as antineoplastic.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CD123-targeted protein-drug conjugate/immunotoxin; mechanistically distinct from conventional cytotoxic chemotherapy per trial documentation) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. TFDA label warnings/contraindications have not yet been retrieved for this candidate (data gap DG001, severity: Blocking) — this must be resolved before any S1 safety pre-assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has zero clinical trial or literature evidence (L5) and no plausible mechanistic link between CD123-targeted cytotoxic therapy and esotropia. The evidence pack's own rationale characterizes this as lacking biological plausibility, consistent with a TxGNN false-positive/model-noise signal rather than an actionable repurposing lead.
To proceed, the following is needed:
- TFDA/official label data (warnings, contraindications, DDI) — currently blocking (DG001)
- Confirmed mechanism of action (DrugBank MOA) — currently missing (DG002)
- Independent mechanistic or preclinical rationale connecting CD123 biology to ophthalmologic/neuromuscular conditions, if this signal is to be pursued further
- Note: Among the other ranked candidates in this evidence pack, rank 2 ("pre-malignant neoplasm") is associated with 5 active/ongoing clinical trials involving tagraxofusp in AML, BPDCN, and high-risk MDS populations. While these trials do not directly validate "pre-malignant neoplasm" as a distinct indication, they reflect real, ongoing clinical development within the drug's existing disease area and may warrant separate review in preference to this candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.